Gregg Gilbert
Stock Analyst at Truist Securities
(2.27)
# 2,729
Out of 5,242 analysts
91
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $18.32 | -7.21% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $34.22 | +8.12% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $58.54 | +43.49% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $1,018.87 | -48.47% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $6.59 | +97.27% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $17.75 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $113.00 | -17.70% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $20.47 | +134.49% | 2 | Feb 2, 2021 | |
| CHRS Coherus Oncology | Initiates: Buy | $26 | $1.51 | +1,621.85% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $0.6379 | +23,414.66% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $11.16 | +598.92% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $79.71 | -2.15% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $34.32 | -47.55% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $217.75 | - | 7 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $239.01 | -26.78% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $212.30 | -68.91% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $18.32
Upside: -7.21%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $34.22
Upside: +8.12%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $58.54
Upside: +43.49%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $1,018.87
Upside: -48.47%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $6.59
Upside: +97.27%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $17.75
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $113.00
Upside: -17.70%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $20.47
Upside: +134.49%
Coherus Oncology
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $1.51
Upside: +1,621.85%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $0.6379
Upside: +23,414.66%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $11.16
Upside: +598.92%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $79.71
Upside: -2.15%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $34.32
Upside: -47.55%
Nov 20, 2017
Downgrades: Sell
Price Target: n/a
Current: $217.75
Upside: -
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $239.01
Upside: -26.78%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $212.30
Upside: -68.91%